618 related articles for article (PubMed ID: 9343181)
21. V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.
Laakso MM; Lee FH; Haggarty B; Agrawal C; Nolan KM; Biscone M; Romano J; Jordan AP; Leslie GJ; Meissner EG; Su L; Hoxie JA; Doms RW
PLoS Pathog; 2007 Aug; 3(8):e117. PubMed ID: 17722977
[TBL] [Abstract][Full Text] [Related]
22. Human immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans.
Mondor I; Ugolini S; Sattentau QJ
J Virol; 1998 May; 72(5):3623-34. PubMed ID: 9557643
[TBL] [Abstract][Full Text] [Related]
23. Human immunodeficiency virus type 1 entry into T cells: more-rapid escape from an anti-V3 loop than from an antireceptor antibody.
Lu S; Putney SD; Robinson HL
J Virol; 1992 Apr; 66(4):2547-50. PubMed ID: 1548779
[TBL] [Abstract][Full Text] [Related]
24. Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.
Peachman KK; Karasavvas N; Chenine AL; McLinden R; Rerks-Ngarm S; Jaranit K; Nitayaphan S; Pitisuttithum P; Tovanabutra S; Zolla-Pazner S; Michael NL; Kim JH; Alving CR; Rao M
PLoS One; 2015; 10(12):e0143895. PubMed ID: 26625359
[TBL] [Abstract][Full Text] [Related]
25. Nonneutralizing antibodies to the CD4-binding site on the gp120 subunit of human immunodeficiency virus type 1 do not interfere with the activity of a neutralizing antibody against the same site.
Herrera C; Spenlehauer C; Fung MS; Burton DR; Beddows S; Moore JP
J Virol; 2003 Jan; 77(2):1084-91. PubMed ID: 12502824
[TBL] [Abstract][Full Text] [Related]
26. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
[TBL] [Abstract][Full Text] [Related]
27. T-cell membrane-associated serine protease, tryptase TL2, binds human immunodeficiency virus type 1 gp120 and cleaves the third-variable-domain loop of gp120. Neutralizing antibodies of human immunodeficiency virus type 1 inhibit cleavage of gp120.
Niwa Y; Yano M; Futaki S; Okumura Y; Kido H
Eur J Biochem; 1996 Apr; 237(1):64-70. PubMed ID: 8620895
[TBL] [Abstract][Full Text] [Related]
28. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.
Ly A; Stamatatos L
J Virol; 2000 Aug; 74(15):6769-76. PubMed ID: 10888615
[TBL] [Abstract][Full Text] [Related]
29. Dextran sulfate blocks antibody binding to the principal neutralizing domain of human immunodeficiency virus type 1 without interfering with gp120-CD4 interactions.
Callahan LN; Phelan M; Mallinson M; Norcross MA
J Virol; 1991 Mar; 65(3):1543-50. PubMed ID: 1995952
[TBL] [Abstract][Full Text] [Related]
30. The v3 loop is accessible on the surface of most human immunodeficiency virus type 1 primary isolates and serves as a neutralization epitope.
Gorny MK; Revesz K; Williams C; Volsky B; Louder MK; Anyangwe CA; Krachmarov C; Kayman SC; Pinter A; Nadas A; Nyambi PN; Mascola JR; Zolla-Pazner S
J Virol; 2004 Mar; 78(5):2394-404. PubMed ID: 14963135
[TBL] [Abstract][Full Text] [Related]
31. Unique binding modes for the broad neutralizing activity of single-chain variable fragments (scFv) targeting CD4-induced epitopes.
Tanaka K; Kuwata T; Alam M; Kaplan G; Takahama S; Valdez KPR; Roitburd-Berman A; Gershoni JM; Matsushita S
Retrovirology; 2017 Sep; 14(1):44. PubMed ID: 28938888
[TBL] [Abstract][Full Text] [Related]
32. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
[TBL] [Abstract][Full Text] [Related]
33. Human immunodeficiency virus type 1 neutralization is determined by epitope exposure on the gp120 oligomer.
Sattentau QJ; Moore JP
J Exp Med; 1995 Jul; 182(1):185-96. PubMed ID: 7540648
[TBL] [Abstract][Full Text] [Related]
34. Envelope glycoproteins from human immunodeficiency virus types 1 and 2 and simian immunodeficiency virus can use human CCR5 as a coreceptor for viral entry and make direct CD4-dependent interactions with this chemokine receptor.
Hill CM; Deng H; Unutmaz D; Kewalramani VN; Bastiani L; Gorny MK; Zolla-Pazner S; Littman DR
J Virol; 1997 Sep; 71(9):6296-304. PubMed ID: 9261346
[TBL] [Abstract][Full Text] [Related]
35. Two neutralizing anti-V3 monoclonal antibodies act by affecting different functions of human immunodeficiency virus type 1.
Armstrong SJ; McInerney TL; McLain L; Wahren B; Hinkula J; Levi M; Dimmock NJ
J Gen Virol; 1996 Dec; 77 ( Pt 12)():2931-41. PubMed ID: 9000083
[TBL] [Abstract][Full Text] [Related]
36. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.
Wu L; Gerard NP; Wyatt R; Choe H; Parolin C; Ruffing N; Borsetti A; Cardoso AA; Desjardin E; Newman W; Gerard C; Sodroski J
Nature; 1996 Nov; 384(6605):179-83. PubMed ID: 8906795
[TBL] [Abstract][Full Text] [Related]
37. Recombinant CD4-selected human immunodeficiency virus type 1 variants with reduced gp120 affinity for CD4 and increased cell fusion capacity.
McKeating J; Balfe P; Clapham P; Weiss RA
J Virol; 1991 Sep; 65(9):4777-85. PubMed ID: 1870202
[TBL] [Abstract][Full Text] [Related]
38. Determinants of human immunodeficiency virus type 1 envelope glycoprotein activation by soluble CD4 and monoclonal antibodies.
Sullivan N; Sun Y; Binley J; Lee J; Barbas CF; Parren PW; Burton DR; Sodroski J
J Virol; 1998 Aug; 72(8):6332-8. PubMed ID: 9658072
[TBL] [Abstract][Full Text] [Related]
39. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition.
Koch M; Pancera M; Kwong PD; Kolchinsky P; Grundner C; Wang L; Hendrickson WA; Sodroski J; Wyatt R
Virology; 2003 Sep; 313(2):387-400. PubMed ID: 12954207
[TBL] [Abstract][Full Text] [Related]
40. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine.
Rovinski B; Haynes JR; Cao SX; James O; Sia C; Zolla-Pazner S; Matthews TJ; Klein MH
J Virol; 1992 Jul; 66(7):4003-12. PubMed ID: 1602531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
